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A B S T R A C T
Prescribing of statins showed an increasing trend in all developed countries, during the last two decades. The aim of
this study was to research the trends in statin consumption in the period from 2004 to 2012 as well as trends of cardio-
vascular mortality during the 1990 to 2012 period, and to compare them between Croatia and several neighbouring
countries. Data on statin expenditures and consumption expresed in defined daily doses per 1000 inhabitants per day
(DDD/TID), were taken from annual reports of Croatian Agency for Medicinal Products and Medical Devices (HAL-
MED). Data on crude mortality rates and standardized cardiovascular mortality rates, were taken from the Croatian
Health Statistics Yearbooks. The utilization of statins increased by 196.7% during the observed period, with the highest
consumption of atorvastatin and simvastatin. Financial expenditure of statins expanded at much faster rate in compari-
son with overall drug costs. Cardiovascular mortality rates decreased slightly, while maintaining higher level in com-
parison with some neighbouring countries.
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Introduction
A trend of reduction in overall cardiovascular mortal-
ity and mortality from coronary heart disease started in
developed countries already in the 1950’s, but with sig-
nificant dissimilarities between countries, regions and
ethnic or social groups. This phenomenon is explained
primarily by improvement in socio-economic quality of
life and by developments in health care, such as introduc-
tion of new drug classes and new procedures and tech-
niques in interventional cardiology, in addition to im-
provement of organisational aspects of emergency ca-
re1–5. Most of the interventions resulted in decrease of
mortality among selected groups of patients (in con-
trolled trials) or subjects with increased cardiovascular
risks. However, as a rule, there was no definite conclu-
sion regarding effect on the population, as the most rele-
vant for public health planning and organisation of
health care. In the last 15 years prescribing of statins
showed an increasing trend in all developed countries,
therefore also in Croatia, probably as a result of im-
proved understanding of benefits of this therapeutic
group in prevention of cardiovascular mortality. Numer-
ous well conducted clinical trials demonstrated their
unquestionable efficacy in reduction of cardiovascular
morbidity and mortality, since their introduction in clini-
cal practice, in the beginning of 1990-ties, in thoroughly
selected population groups. The rise of their utilization
in the entire population has been took for granted, there-
fore, as desirable and benefitial trend also in primary
prevention, with the aim of controlling modifiable risk
factors involved in pathogenesis of mainly coronary heart
disease.
In Croatia, statins are introduced in the middle of
1990-ties. The Croatian Health Insurance Fund (CHIF)
has, in the beginning, restricted their use to prescribing
only after recommendation of cardiologist, because of
their high price. The recommendations are later incorpo-
rated, as restricted indications, into the basic and supple-
mentary lists of medicines. High costs of treatment and
prevention were managed by prescribing restrictions, as
well as lowering of drug prices in direct negotiations be-
tween the CHIF and pharmaceutical industry, and stim-
ulation of generic prescribing6,7.
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In 2011, mandatory recommendation of cardiologist
was abolished, but indication restrictions remained. In
seconary prevention, indication guidelines enclosed pa-
tients after myocardial infarction, ischemic brain insult,
transitory ischemic attack, carotide plaque or peripheral
arterial occlusive disease verifyed by ultrasound, coro-
nary heart disease verified by coronarography, or electro-
cardiography (ECG) stress test, and to diabetics with to-
tal cholesterol above 5 mmol/L. In primary prevention
they ought to be prescribed to persons with total choles-
terol above 7 mmol/L in two separate measurements, but
only after at least three months of dietary and lifestyle
change attempts, also in younger persons, and those
above 50, if their Systematic Coronary Risk Evaluation
(SCORE) result exceeds 10 percent8.
In Croatia, however, despite restrictions, there is a
continuous rise of consumption9,10. To what degree is
that increase correlated with cardiovascular mortality, as
the most important reason of their use, and to what de-
gree is financial spending sustainable in the time of eco-
nomic recession, remains to be understood. Hence, the
aim of this study was to explore trends in statins con-
sumption in the period 2004 and 2012 and trends of car-
diovascular mortality in the period from 1990 to 2012, in
Croatia and several neighbouring countries.
Materials and Methods
This population observational study was based on
compiled data on drug utilization, as well as age stan-
dardized rates of cardiovascular mortality. Data on con-
sumption of drugs for dyslipidemia (inhibitors of HMG
CoA reductase, statins, C10AA), were taken from annual
reports of Croatian Agency for Medicinal Products and
Medical Devices (HALMED), from 2004–201211.
In the Agency reports, mainly outpatient and total
utilization were traced, while hospital utilization was
only roughly estimated between 2.98–3.7% of the total
utilisation. The utilization was measured systematically
from 2004, according to both ATC/DDD methodology and
financial indicators, based on data from Croatian phar-
macies. Financial spending was expressed in Croatian
kunas (international abbreviation: HRK): 1 EUR = 7.625
HRK, 12.04.2014, and therapeutic consumption in num-
ber of defined daily doses per 1000 inhabitants per day
(DDD/TID), as standardized measure on the population
level, for both the statins in total and individual generic
drugs, simvastatin (ATC C10AA01) and atorvastatin
(ATC C10AA05), as the most frequently prescribed. Fi-
nancial and therapeutic consumption of other drugs for
dyslipidemia (fenofibrate, gemfibrozil, cholestiramine)
registered in Croatia was not considered, due to their
marginal (compared with statins) financial and thera-
peutic significance.
Data on overall mortality and age standardized car-
diovascular mortality rates, coronary heart disease mor-
tality and cerebrovascular disease mortality rates, for
the age group 0–64, and per 100 000 inhabitans, were
taken from the Croatian Health Statistics Yearbooks
(CHSY), for the period between 1980 and 201212. Except
for Croatia, the same data were analysed for several
neighbouring countries, Slovenia, Hungary, Czech Re-
public and Austria, as well as for group of 27 European
Union countries before joining of Croatia in 2013 (EU27).
Results
Results are divided into two units: trends in statin
consumption and trends in cardiovascular mortality.
Trends in statins consumption
Total drug utilization in Croatian population, in the
last 10 years, expressed as DDD/TID was in constant
rise. In 2004 consumption rate was 658.1 DDD/TID and
in 2012 – 926.9 DDD/TID (increase of 40.7%). A genera-
tor of that increase was mainly outpatient statin pre-
scriptions issued by family physicians. Hospital use was
roughly between 2.98–3.7% of the total drug consump-
tion from 2004 to 2007, and around 0.5 DDD/TID be-
tween 2008 and 2012.
From 2004 to 2012 the use of statins grew up, from
28.1 to 83.5 DDD/TID (increase by 196.7%), with sharp
fall to 48.6 DDD/TID in 2011. Consumption of individual
statins followed this trend. Simvastatin use increased at
a rate of 64% until 2010, but fell in the last two years.
From the eighth position on the rank list of most fre-
quently prescribed drugs in 2004, simvastatin dropped to
the seventeenth. Atorvastatin use grew sharply until
2010, from 8.9 in 2004 to 47.9 DDD/TID in 2010 (in-
crease by 440%), followed by decrease to 26.9 DDD/TID
in 2012. From the fourteenth position on the rank list, it
shifted to the second in 2010. Fluvastatin was prescribed
in greatly lesser proportion, but again, with a trend of
slight growth, from 1.5 in 2004 to 6.5 DDD/TID in 2012.
The use of newly registered rosuvastatin, available since
2010, increased for 20 times, from 0.4 to 7.0 DDD/TID in
2012 (Figure 1).
In 2004, the overall financial spending on drugs in
Croatia was 3.82 billions of HRK (around 501 millions of
EUR, according to exchange rate from 12.04.2014). Ap-
@. Vojvodi} and D. [timac: Overuse of Statins in Croatia, Coll. Antropol. 38 (2014) Suppl. 2: 73–78
74
Fig. 1. Trends in overall statin consumption in Croatia from
2004–2012 (in DDD/TID).
proximately 90% of that amount were drugs on prescrip-
tion regime, and therefore reimbursable by the CHIF. The
overall costs were roughly equal from 2004 to 2007, while
in the last few years increased by 32.7% – from 3.82 bil-
lions of HRK in 2004 to 5.07 billions in 2012 (Figure 2).
Financial expenditure of statins expanded at much
faster rate (at a rate of 53%), in comparison with the
drug costs in total, from 161.76 millions of HRK in 2004
to 247.43 millions of HRK in 2012. Simvastatin and
atorvastatin shared the greatest proportion in costs.
Simvastatin expenditure decreased from 102.4 millions
of HRK in 2004 to 50.36 millions of HRK in 2012, replac-
ing its first position on the rank list of 25 top sales in
2004 with the forteenth position in 2012. Atorvastatin
sales, in the same period, advanced from 45.5 millions of
HRK in 2004 to 114.05 millions in 2012 (increase by
150%), moving from the eleventh position on the rank
list in 2004 to the first position in the year 2008 already
(Figure 3). In the period of three years, rosuvastatin
costs greatly advanced from negligible couple of thou-
sands to significant 29.03 millions HRK, in 2012.
Trends in cardiovascular mortality
The crude death rates in Croatia fluctuated between
10.9/1000 inhabitants in 1990 to 12.1/1000 inhabitants
in 2012, or expressed in absolute numbers, from 50,100
to 52,400 deaths per year (Figure 4).
Standardized cardiovascular mortality rates for the
age 0 – 64 in all selected countries decreased continually.
Only in Hungary, a slight increase from 1980 to 1993 was
recorded, followed by a decline. Mortality rates, however,
varied among countries for more than two times. In 2011
the highest rate was in Hungary (98.6/100,000), than in
Czech Republic (59.9) and Croatia (59.8). The lowest rate
was in Austria (29.8) (Figure 5). Similar trends existed
with age standardized rates from ischemic heart disease
and cerebrovascular disease (Figures 6 and 7).
Standardized mortality rates from ischemic heart dis-
eases for the age 0–64 varied between the countries. In
the EU27 group of countries, Austria and Slovenia, a
trend of steady continuous decline was present, from lev-
els, generally, two times lower than in Hungary and
Czech Republic. The later showed a sharp decline, while
mortality in Hungary, although decreasing, remained the
highest during the entire period. In Croatia the rates
slightly increased, from 38.9/100,000 in 1990 to 43.5/
100,000 1998, and then declined to 30.5/100,000 in 2011.
Despite that, in 2011, standardized mortality rate from
ischemic heart diseases for the age 0–64, in our country
was almost two times greater than in Slovenia, Austria
and EU27 group (Figure 6).
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Fig. 2. Overall financial spending on drugs in Croatia from
2004–2012 (in billions of HRK).
Fig. 3. Overall financial spending on statins in total, simvasta-
tin and atorvastatin in Croatia from 2004–2012 (in millions of
HRK).
Fig. 4. Trends in crude death rates and absolute number of
deaths in Croatia from 1980 to 2012.
Fig. 5. Trends in standardized cardiovascular mortality rates
(age 0–64, per 100.000 inhabitants) in Croatia, Austria, Czech
Republic, Hungary, Slovenia and EU27, from 1980 to 2012.
Trends in standardized mortality rates from cere-
brovascular disease continually declined in all countries.
Somewhat greater oscillations were noticeable only in
Croatia, between 1995 and 2001. The highest rate was in
1996, 34.6/10,000, but than declined towards present
time, remaining generally above average among the se-
lected group of countries, except for Hungary. In compar-
ison with Slovenia and the EU27 group, the rate was al-
most twice greater, while compared with Austria, it was
more than three times (Figure 7).
Discussion
Concerning the proven efficacy of statins in the treat-
ment of ischemic heart disease, as well as in secondary
prevention, one would expect a significant decline in car-
diovascular mortality after their introduction in clinical
practice. However, the results of this investigation sug-
gest that there is no, especially after 1995 (the registra-
tion of simvastatin in Croatia) any change in the trends.
While the use of statins almost doubled from 2004, car-
diovascular mortality rates decreased in balanced linear
mode since 1990-ties. Trends in ischemic heart disease
mortality also declined continually in all selected coun-
tries, except in Croatia, where it was relatively station-
ary. Standardized rates for cerebrovascular mortality are
also twice greater in Croatia, in comparison with neigh-
bouring Slovenia, and the EU27 group, and three times
higher than in Austria.
While in this study we selected mortality as the most
important trend for comparison with the utilization of
drugs for dyslipidemia, another research compared the
use of hypolipemics in the City of Zagreb with the rate of
hospital admissions due to acute complications of cardio-
vascular diseases10,13. The rise of consumption from 31
DDD/TID in 2001 to 72.4 DDD/TID in 2006 was followed
by a decline in hospital admissions by 18.5%. It was con-
cluded that the declining trend was a result of improved
secondary prevention, on a ground of positive impact of
statins. The conclusion was probably correct from the as-
pect of secondary prevention and morbidity, but not suf-
ficient enough for interpretation of considerably lesser
effect on mortality.
Although the benefitial effect of statins on cardiovas-
cular mortality is substantiated in numerous clinical tri-
als, the question of their effect on the population level
should be examined in a wider frame, having in mind the
complexity of cardiovascular diseases. There is, in partic-
ular, a great influence of social gradient, a cluster of
mixed social, cultural and economic factors, in their
epidemiology14,15. According to Marmont and al., social
gradient could potentially be involved with more than a
half of share16. Also classical risk factors can not be un-
derstood out of social context, including the employment
status17,18, important in Croatia nowdays. Interventions
aiming at reduction of risks by modifying behavioural
factors had, regretably, limited achievements, and in
Croatia being not carried out in systemic manner. If only
hypertension and diabetes are considered as principal
risk factors, then interventions aimed at their control
again failed to reach any conclusive outcomes, because
there are only 63% adequatelly controlled hypertensive
patients and 22.3–34.7% diabetics12,19. Because of that,
only comprehensive intervention, inluding biological, so-
cial and behavioural factors, on both individual and pop-
ulation level, provides some chance for success20.
If the utilization of statins is understood as one of
many procedures, being a part of complex intervention,
then our investigation demonstrates that their consump-
tion, with the increase rate of 76% in the observed pe-
riod, is overabundant. The use is even more exessive, if
we compare regional differences. In the City of Zagreb
only, the consumption was twice greater, than in our
study: 72.4 DDD/TID in 2006 and 98.98 DDD/TID in
20089,10,21. However, both the overall drug consumption
and the use of cardiovascular medicines in Zagreb are
above the country’s average. The possible explanations
are that there are situated 43% of all health resources as
well as centres of clinical excellence, with greater flow of
scientific information than in the country’s interior. Fur-
thermore, near 50,000 employees commute daily in the
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Fig. 6. Trends in standardized mortality rates from ischemic
heart disease (age 0–64, per 100.000 inhabitants) in Croatia,
Austria, Czech Republic, Hungary, Slovenia and EU27, from
1980 to 2012.
Fig. 7. Trends in standardized mortality rates from cerebrovas-
cular disease (age 0–64, per 100.000 inhabitants) in Croatia,
Austria, Czech Republic, Hungary, Slovenia and EU27, from
1980 to 2012.
city, and at least part of them use city’s health care facili-
ties. But, it could also be understood as an additional ex-
ample of health inequalities21.
It seems that administrative measures against over-
spending of statins, such as prescribing after recommen-
dation of cardiologist, restricted indications and price
cutting in negotiations with pharmaceutical industry,
failed to accompllish any measurable effect. On the con-
trary, when family physicians were authorized in 2011 to
prescibe without prior recommendation, but within the
framework of guidelines of the CHIF, there was a decline
in prescriptions and the volume of consumption, in par-
ticular of simvastatin and atorvastatin. The only ques-
tion is whether the trend is temporary or sustainable in
the next period. Financial spending in HRK needs special
attention, not only because of current economic reces-
sion in Croatia, but also because of their rapidly increas-
ing proportion in healthcare costs, which rise in all devel-
oped countries due to their high price. The overall drug
spending in Croatia approached about 25% of total health-
care costs, with 5% of that amount to statins alone (247.3
millions of HRK).
The structure of expenditure also reflects great influ-
ence of pharmaceutical industry. For example, in 2001,
simvastatin costed between 70 and 176 HRK, depending
on the size of package, and whether it was generic or
brand, while atorvastatin cost, in that period available
only as a brand product, was between 160 and 320 HRK,
being from 2008 to 2012 on the first position of drug
sales. The case of rosuvastatin, being on positive list
since 2010, is exemplary, since its sales from a couple of
thousands of HRK grew to impressive 29.03 millions of
HRK in 2012 (3.93 millions of EUR)11. In Croatia there is
a scarcity of cost-benefit research, especially in this seg-
ment of healthcare spending, and therefore no informa-
tion if such a great investments in this therapeutic group
met expectations. It would, probably be more cost-effec-
tive to redirect a part of financial means to other, more
certain interventions, for reducing a disease burden21.
Regarding the future trend of excessive statin con-
sumption, there are two other questions that need to be
addressed. The first is related to the changes in the new-
est clinical guidelines from the American College of Car-
diology and American Heart Association, which provok-
ed considerable concern among health professionals. In
patients with already known cardiovascular risk, for ex-
ample, statins are indicated irrespective of LDL values.
They are recommended also for primary prevention in di-
abetics with LDL above 1.81 mmol/L or in persons with
the overall 10-year SCORE cardiovascular risk above
7.5%22. According to Pencini and al. it means that the
statin use will greatly increase, from approximately 30.4
to 87.4%, in the USA, among persons between 60 and 75,
and with no known cardiovascular disease24. Further-
more, near 12.8 millions of Americans, mostly elderly,
but without heart disease, should take statin. »Take a
statin, and your chance for cardiovascular event will be
prolonged for a couple of days«, says Mascitelli25.
The second question is related to the adverse effects.
In our country, regretably, there is a lack of precise data
on the number of reports of adverse events to statins, but
elswhere there is abundancy of such reports pointing out
to potentially serious complications: statin myopathy,
hepatic dysfunction, increased risk of developing diabe-
tes, confusion, aggressive behaviour, cognitive distur-
bances, memory loss, immunoallergic skin reactions etc26–29.
This study has, however, advantages and limitations.
Advantages are in the use of data from the official na-
tional health statistics, which is commonly used in plan-
ning of health care, and in analyzing mortality trends on
the population level during more than three decades. We
could not, however, suggest any causality relation in this
type of investigation, nor explore individual factors in-
volved in the consumption of statins. How important is
the role of clinical guidelines, pharmaceutical promotion,
share of responsibilities between primary and secondary
care, or prescribing habits and attitudes of family practi-
tioners, as well as degree of patients’ adherence, is also
worth exploring.
Conclusions
The overall drug utilization in Croatian population
was in constant rise. In that widespread increase in the
use of medicines, outpatient statin prescribing increased
more than in other therapeutic groups, with the greater
rise of atorvastatin compared with simvastatin, and the
greatest of rosuvastatin. Financial expenditure of statins
expanded at much faster rate, in comparison with the
drug costs in total, which is also an important fact in to-
day’s financial situation in Croatia. In the same time,
standardized cardiovascular mortality rates and ische-
mic and cerebrovascular rates for the age 0–64 decreased
in balanced linear mode since 1990-ties, while maintain-
ing higher level in comparison with some neighbouring
countries.
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TRENDOVI KRETANJA POTRO[NJE STATINA I SMRTNOST OD KARDIOVASKULARNIH
BOLESTI U HRVATSKOJ OD 2004–2012
S A @ E T A K
U zadnja dva desetlje}a, potro{nja statina bilje`i zna~ajan rast u svim razvijenim zemljama. Cilj ovoga rada bio je
istra`iti trend potro{nje statina od 2004.–2012. godine u Hrvatskoj te istra`iti trend kardiovaskularne smrtnosti u
razdoblju od 1980.–2012. i usporediti ga sa susjednim zemljama. Podaci o financijskoj potro{nji statina te o potro{nji
iskazanoj brojem DDD/1000/dan dobiveni su iz izvje{}a Hrvatske agencije za lijekove i medicinske proizvode (HAL-
MED). Podaci o ukupnoj smrtnosti te standardiziranim stopama smrtnosti od kardiovaskularnih bolesti dobiveni su iz
zdravstveno statisti~kih ljetopisa Hrvatskog zavoda za javno zdravstvo. Tijekom promatranog razdoblja, potro{nja
statina porasla je 196,7%, a najve}u potro{nju unutar te skupine, kroz promatrano razdoblje pokazuju simvastatin i
atorvastatin. Prema finacijskim pokazateljima potro{nja statina je rasla zna~ajno vi{e od ukupne potro{nje lijekova.
Iako stope smrtnosti od kardiovaskularnih bolesti tijekom promatranog razdoblja pokazuju blagi pad, one su tijekom
~itavog razdoblja znatno vi{e nego u nekim susjednim zemljama.
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